|
Market Cap (3-Jul) $147,983,008 (477th) |
Close (30-Jun) $0.99 |
Volume (30-Jun) 1,077,429 |
Shortsold (19-Jun) 1,473,254 (0.38%) (338th) |
|
52w High $0.66 |
52w Low $0.165 |
P/E - |
EPS -0.05 |
PAR released this announcement to the ASX on 12 April 2022, 11:38. The announcement is marked as price sensitive, and is 4 page(s) in length and 115.14kb in size.
You can view all announcements from PAR and see how they appear on a price chart on the announcements page.
At the date of this announcement, PAR was 3.520% short sold according to ASIC data. It was ranked the 56th most shorted stock on the ASX. It remains ranked 338th as of the latest reported data (19 June 2025).
| Other Recent Announcements from PAR | |
|---|---|
| Notification of cessation of securities - PAR | 29 June 2023, 16:43 |
| Primary and Secondary endpoints met in MPS I Trial | 6 June 2023, 12:28 |
| iPPS shows 3-year equivalent durability in OA Canine Study | 1 June 2023, 8:21 |
| FDA Grants Paradigm Fast Track Designation For OA | 12 April 2022, 11:38 |
| UK ethics and regulatory approval for Phase 3 study | 17 March 2022, 9:20 |
| Change in substantial holding | 9 March 2022, 16:14 |
| Change of Director's Interest Notice | 9 March 2022, 16:13 |
You must be logged in to post a reply.
Paradigm Biopharmaceuticals 